UBS Maintains Buy on Eli Lilly, Lowers Price Target to $1050
Eli Lilly Analyst Ratings
Abbott Gains After Upcoming Baby Formula Case Thrown Out
Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?
Catalyst Watch: Powell Presser, AMD Earnings, IBM Event, and Lions Gate Splits in Two
This Market Is The Buying Opportunity Of A Lifetime
Novo Nordisk Says Oral Version of Wegovy Accepted for FDA Review
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $320
Amgen Analyst Ratings
Cigna to Launch Specialized GLP-1 Pharmacy Next Month
Amgen Unusual Options Activity For May 02
Eli Lilly's Options Frenzy: What You Need to Know
Sector Update: Health Care Stocks Rise Premarket Friday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Weigh Mix of Earnings, Rise in US Nonfarm Payrolls
4 Stocks to Watch on Friday: XOM, CVX, AMGN and TTWO
SA Charts: How U.S. Manufacturing Jobs Have Declined Since the 1980s
Earnings Call Summary | Amgen(AMGN.US) Q1 2025 Earnings Conference
Amedisys Gains After Announcing New Divestiture Agreements in UnitedHealth Deal
Amgen Beats on Both Lines and Reaffirms Guidance; Stock Flat Post Market
What happened? Eli Lilly and Co's Q1 revenue surged by 45%, but the stock price plummeted more than 10% during trading.
In the first quarter, Eli Lilly and Co's weight loss drug Zepbound saw sales increase more than threefold, while the annual EPS guidance was lowered by over 7% due to acquisition-related expenses, with the annual revenue guidance remaining unchanged, but only reflecting the impact of Trump tariffs as of early May. The chain pharmacy giant CVX has decided to include Novo-Nordisk A/S's Wegovy as the preferred option in its main prescription drug catalog starting in July, while Zepbound was not included, with the CEO of Eli Lilly and Co calling it "a step backward."